Dr Karim Fizazi discusses his phase III trial which compared the efficacy of denosumab with zoledronic acid in patients with matastatic castration-resistant prostate cancer. The trial demonstrated that denosumab is superior to zoledronic acid in delaying or preventing skeletal-related events. Dr Fizazi goes on to outline his aims for further research into denosumab and explains the side-effects that the treatment can have on the patients.This interview is supported by an unrestricted educational grant from AMGEN.